中国医药：子公司获得药品注册证书

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration, which is expected to enhance the company's product line and provide valuable experience for future generic drug development [1] Group 1 - The drug Dabigatran Etexilate is a direct thrombin inhibitor used primarily to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and lower the risk of recurrence of these conditions [1] - The approval of Dabigatran Etexilate Capsules will enrich the company's product matrix and further improve its product layout [1] - The experience gained from this approval will be beneficial for the company's future generic drug development [1]